Home Journals Articles Updates About
CN
image
收藏切换
Research status of rimegepant in migraine treatment
收藏切换
PDF
Wen-hui LIU1, 2, Si-jie ZHANG1, 2, Yan WANG2, Si-qi OUYANG2, Yong-liang ZHU2, Dong-jun WAN2
Chinese Journal of Clinical Pharmacology | 2026, 42(6) : 885 - 892
Less
收藏切换
Chinese Journal of Clinical Pharmacology | 2026, 42(6): 885-892
• Review •
Research status of rimegepant in migraine treatment
Full
Wen-hui LIU1, 2, Si-jie ZHANG1, 2, Yan WANG2, Si-qi OUYANG2, Yong-liang ZHU2, Dong-jun WAN2
Affiliations
  • 1.Gansu University of Chinese Medicine, Lanzhou 730000, Gansu Province, China
  • 2.The 940th Hospital of the Joint Logistics Support Force of the Chinese People’s Liberation Army, Lanzhou 730050, Gansu Province, China
Published: 2026-03-28 doi: 10.13699/j.cnki.1001-6821.2026.06.021
Outline
收藏切换

Migraine is a highly disabling chronic disease that significantly affects patients’ quality of life. Conventional therapeutic drugs have limited application due to their insufficient efficacy, numerous contraindications and high risk of induce medication-overuse headache. With the in-depth research on the pathogenesis of migraine, the calcitonin gene-related peptide (CGRP) receptor has emerged as a noval target for the treatment and prevention of migraine. As a noval CGRP receptor antagonist, rimegepant was approved for marketing in China in 2024. Reserach has shown that rimegepant can simultaneously reduce the frequency of migraine attacks and the medication dosage in the acute phase. It is currently the first and only drug that can be used for both acute and preventive treatment of migraine, which makes up for the shortcomings of conventional therapeutic drugs. This article systematically reviews the research progress of rimegepant in the treatment of migraine, including its mechanism of action, pharmacokinetic characteristics, clinical trial, and safety evaluation, aiming to provide a evidence for the clinial treatment of migraine.

rimegepant  /  migraine  /  calcitonin gene-related peptide  /  calcitonin gene-related peptide receptor antagonist
Wen-hui LIU, Si-jie ZHANG, Yan WANG, Si-qi OUYANG, Yong-liang ZHU, Dong-jun WAN. Research status of rimegepant in migraine treatment[J]. Chinese Journal of Clinical Pharmacology, 2026 , 42 (6) : 885 -892 . DOI: 10.13699/j.cnki.1001-6821.2026.06.021
Appendix
Less
Year 2026 volume 42 Issue 6
PDF
174
29
Cite this Article
BibTeX
Article Info
doi: 10.13699/j.cnki.1001-6821.2026.06.021
  • Receive Date：2025-09-22
  • Online Date：2026-08-06
  • Published：2026-03-28
Article Data
Affiliations
History
  • Received：2025-09-22
Funding
Affiliations
    1.Gansu University of Chinese Medicine, Lanzhou 730000, Gansu Province, China
    2.The 940th Hospital of the Joint Logistics Support Force of the Chinese People’s Liberation Army, Lanzhou 730050, Gansu Province, China
References
Share
https://castjournals.cast.org.cn/joweb/zglcylxzz/EN/10.13699/j.cnki.1001-6821.2026.06.021
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family		 属数
Number of
genus		 种数
Number of
species		 占总种数比例
Percentage of
total species (%)		 属
Genus		 种数
Number of
species		 占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT
Links
Articles
Latest Articles
Most Read
Collections
Updates
Events
News
Multimedia
About
About Us
Contact
No. 86 Xueyuan South Road, Haidian District, Beijing
100081
010-62199257
qkjq@cast.org.cn

Copyright © 2025 China Association for Science and Technology. All rights reserved. For all open access content, the relevant licensing terms apply.
Sponsored by the Office of the Leading Group for Cybersecurity and Informatization of CAST, and supported by Science and Technology Review Publishing House